Litigation Details for Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2021)

Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2021)

Docket	1:21-cv-00612	Date Filed	2021-04-29
Court	District Court, D. Delaware	Date Terminated	2021-10-19
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	MAYNE PHARMA LLC
Patents	10,857,159
Attorneys	John P. Snow
Firms	KL Gates LLP
Link to Docket	External link to docket

Details for Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-29				External link to document

Mayne Pharma v. Padagis Israel: Doryx Patent Litigation Summary and Generic Entry Analysis

Last updated: September 9, 2026

Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd., No. 1:21-cv-00612, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Padagis’ proposed generic version of Mayne Pharma’s Doryx delayed-release doxycycline product. Mayne sued after receiving a Paragraph IV certification. The case was resolved without a public merits judgment, and the publicly available docket does not disclose the settlement’s commercial terms or an authorized generic launch date.

What drug and patents were involved in Mayne Pharma v. Padagis?

The dispute concerned doxycycline hyclate delayed-release tablets, including the Doryx product line marketed by Mayne Pharma.

Doryx is an oral tetracycline product indicated for infections susceptible to doxycycline and for adjunctive treatment of severe acne. Its commercial differentiation depends on delayed-release technology designed to reduce gastrointestinal irritation and control release of doxycycline in the gastrointestinal tract.

Item	Case information
Plaintiff	Mayne Pharma LLC
Defendant	Padagis Israel Pharmaceuticals Ltd.
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-00612
Filing year	2021
Regulatory framework	Hatch-Waxman Act
Challenged product	Generic doxycycline hyclate delayed-release tablets
Reference product	Doryx and related Doryx delayed-release presentations
Case posture	ANDA patent litigation
Resolution	Settlement and termination without a public merits judgment
Public settlement terms	Not disclosed

The complaint asserted patent rights associated with the formulation and delivery of doxycycline in delayed-release tablets. The asserted estate was directed at product characteristics that distinguish Doryx from immediate-release doxycycline, including release behavior, composition, and dosage-form performance.

Public docket materials should be read with the FDA Orange Book for the exact patent-by-patent listing applicable to the challenged Doryx presentation. The litigation record does not establish that every Orange Book-listed patent was asserted against Padagis.

What was the legal basis for Mayne Pharma’s lawsuit?

Mayne’s action was based on Padagis’ filing of an abbreviated new drug application, or ANDA, containing a Paragraph IV certification.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The certification gives the patent owner a basis to bring an infringement action under 35 U.S.C. § 271(e)(2), even before the generic product is commercially marketed.

The filing of the lawsuit generally triggers an FDA approval stay of up to 30 months under 21 U.S.C. § 355(j)(5)(B)(iii), unless the case is resolved earlier or the court orders otherwise. The stay protects the listed patent rights while the parties litigate or negotiate.

The public case materials indicate the dispute focused on formulation and delayed-release patent rights rather than on a biosimilar pathway, clinical-trial data, or biologic manufacturing.

What was the litigation timeline?

Date or period	Event
2021	Padagis filed an ANDA with a Paragraph IV certification directed to Doryx-related patent rights.
April 2021	Mayne Pharma filed the Delaware infringement action, No. 1:21-cv-00612.
2021-2022	The parties litigated the ANDA dispute and negotiated a resolution.
Case resolution	The action was terminated pursuant to a confidential settlement.
Post-settlement	No public trial judgment determining patent validity, enforceability, or infringement was entered.

The case did not produce a reported claim-construction ruling, summary-judgment decision, or trial verdict that would establish how the asserted claims should be interpreted. That limits the precedential value of the proceeding.

How did the settlement affect generic entry?

The settlement’s commercial effect cannot be determined from the public docket because the operative business terms were confidential.

The key undisclosed terms normally relevant to generic-entry analysis are:

• Padagis’ agreed launch date.
• Whether Mayne granted a license.
• Whether the license permitted an authorized generic.
• Whether launch was contingent on other Doryx litigation.
• Whether Padagis agreed to waive or withdraw invalidity challenges.
• Whether Mayne made a payment or provided another form of consideration.
• Whether the agreement covered all Doryx strengths and dosage forms.

A confidential settlement does not establish that the patents were valid or infringed. It also does not establish that Padagis’ ANDA product could not have entered the market absent the agreement.

When does Doryx lose exclusivity?

Doryx exclusivity depends on several separate dates rather than one expiration date.

Patent exclusivity

Patent expiration depends on the specific Orange Book-listed patent, patent term adjustment, patent term extension, and any applicable pediatric exclusivity. Formulation patents for delayed-release doxycycline can extend beyond the expiration of earlier compound or composition patents.

The relevant dates must therefore be evaluated separately for:

1. Doxycycline active-ingredient or composition protection.
2. Delayed-release formulation claims.
3. Tablet manufacturing and coating claims.
4. Method-of-use claims.
5. Presentation-specific listings for different strengths.

A generic applicant can challenge the listed patents through Paragraph IV certification or wait for relevant patent expiration and pursue a Paragraph III certification.

Regulatory exclusivity

Doryx is a small-molecule drug. It does not receive the 12-year reference-product exclusivity associated with biologics under the Biologics Price Competition and Innovation Act.

Any applicable FDA exclusivity would depend on the specific original approval, supplement, or three-year exclusivity designation. FDA regulatory exclusivity and patent protection operate independently. Expiration of one does not necessarily eliminate the other.

What is the Orange Book status of Doryx?

Doryx-related patents are evaluated through FDA Orange Book listings tied to particular reference products and dosage forms. Orange Book listings can include patents covering the drug substance, formulation, method of use, or other approved-product attributes.

The Mayne-Padagis dispute should not be interpreted as a challenge to every patent associated with every Doryx presentation. A Paragraph IV case is limited by the patents identified in the ANDA certification and the complaint.

For commercial diligence, the relevant Orange Book questions are:

• Which Doryx National Drug Code and strength did Padagis target?
• Which patents were listed against that reference product?
• Which listed patents were subject to Paragraph IV certification?
• Did Mayne assert all certified patents?
• Did the settlement cover other Doryx products?
• Did any patent remain unchallenged or expire during the case?

The litigation docket and the Orange Book should be reviewed together because the Orange Book identifies listed patents, while the complaint identifies the patents actually asserted in the lawsuit.

What formulation patents protect Doryx?

Doryx’s principal patent risk is associated with delayed-release formulation technology.

Relevant technical protection can include:

• Doxycycline particle size and distribution.
• Enteric or delayed-release coating systems.
• Polymer matrices and release-control layers.
• Tablet composition and excipient selection.
• Protection against premature doxycycline release.
• Dissolution profiles.
• Manufacturing processes used to produce the delayed-release dosage form.

These rights can create practical barriers even when a generic applicant avoids literal infringement of a narrow composition claim. A generic may need to modify its coating system, dissolution profile, excipient package, or manufacturing process to avoid infringement. Those modifications can affect bioequivalence, scale-up, stability, and FDA approval timing.

Method-of-use patents are generally less central to this dispute than formulation patents unless the ANDA label induces use covered by an approved indication. The strength of a method-of-use claim depends heavily on the proposed generic label and whether the claimed use can be removed without making the product non-viable commercially.

How strong was Mayne Pharma’s patent estate?

The estate had meaningful commercial value because delayed-release doxycycline products are differentiated by formulation performance, not merely by the active ingredient.

Its strength can be assessed across four dimensions:

Factor	Assessment
Product differentiation	Stronger than an ordinary immediate-release doxycycline product because delayed release is central to the product profile.
Claim breadth	Depends on whether claims cover broad formulation characteristics or narrow excipient and coating combinations.
Design-around risk	Material. Generic manufacturers may alter coatings, excipients, release profiles, or manufacturing steps.
Litigation precedent	Limited. The Padagis case ended without a public merits decision.

The settlement provides no public evidence that Mayne’s asserted patents would have survived validity or infringement challenges. It does show that the patents were commercially significant enough to support a negotiated resolution before a final judgment.

Which companies were challenging Doryx patent rights?

Padagis was the defendant in this action. Other generic applicants may have pursued separate ANDA strategies involving doxycycline delayed-release products, but the Mayne-Padagis docket should not be used to attribute another company’s certification, product design, or settlement terms to Padagis.

The competitive field includes:

• Mayne Pharma as the branded or authorized commercial sponsor.
• Padagis as the ANDA applicant in this case.
• Other generic pharmaceutical companies that may target doxycycline delayed-release tablets.
• Manufacturers supplying coated-tablet technology, doxycycline active pharmaceutical ingredient, and specialized release-control materials.

Competition is shaped by both patent clearance and manufacturing capability. A company may have a legally viable design-around but still face technical difficulty reproducing the reference product’s dissolution and stability profile.

Did the case involve biosimilar risk?

No. The case involved a small-molecule doxycycline product under the ANDA pathway, not a biologic under the BPCIA.

Accordingly:

• There was no biosimilar interchangeability issue.
• The relevant approval pathway was ANDA approval.
• Patent litigation was governed by Hatch-Waxman procedures.
• The commercial risk was generic substitution and price erosion, not biosimilar penetration.

What generic launch scenarios existed?

Three launch scenarios were possible:

1. At-risk launch: Padagis could launch before final resolution of all patent issues, accepting potential damages and injunction risk.
2. Licensed launch: The settlement could authorize launch on an agreed date, possibly with restrictions or a royalty structure.
3. Post-expiration launch: Padagis could wait until the relevant patent barriers expired or were removed.

The public record does not disclose which commercial structure the parties adopted. The absence of a public merits decision means there is no adjudicated finding that an at-risk launch would have infringed or that the asserted patents were valid.

What revenue exposure did Mayne face?

Doryx revenue exposure arose from potential generic substitution in a branded oral antibiotic market. The commercial impact would depend on:

• The number of approved generic competitors.
• Whether Padagis received a first-filer or other competitive position.
• The agreed launch date.
• The number of Doryx strengths and presentations covered.
• Pharmacy substitution and payer formulary behavior.
• Mayne’s ability to maintain price and market share.
• Availability of an authorized generic.

A single delayed-release generic can cause rapid price erosion if it is therapeutically substitutable and widely distributed. The erosion rate may be slower if the generic has limited strengths, restricted supply, or technical differences that affect substitution.

Public case materials do not establish Mayne’s product-specific revenue exposure or Padagis’ expected market share.

What is the current litigation status?

The litigation was resolved and closed through settlement. There was no publicly reported final judgment on:

• Patent validity.
• Patent enforceability.
• Infringement.
• Claim construction.
• FDA approval timing.
• Generic launch authorization.

The agreement’s confidentiality limits the ability to determine whether Mayne preserved a later launch date, licensed Padagis, authorized a generic, or obtained other restrictions.

Key Takeaways

• Mayne Pharma sued Padagis in Delaware over a Paragraph IV ANDA targeting Doryx-related delayed-release doxycycline tablets.
• The dispute centered on formulation and delayed-release patent rights.
• The case ended through a confidential settlement rather than a public trial judgment.
• No public decision establishes the validity, enforceability, or infringement of the asserted patents.
• The settlement’s launch date, licensing provisions, payment terms, and authorized-generic provisions are not publicly disclosed.
• The case involved Hatch-Waxman generic risk, not biosimilar risk.
• Doryx exclusivity must be analyzed patent by patent and presentation by presentation through the FDA Orange Book.
• Manufacturing capability and formulation design-around risk remain important barriers to generic entry.

FAQs

Was Padagis allowed to launch a generic Doryx product?

The public record does not disclose the settlement’s launch authorization or timing.

Did Mayne Pharma win the patent case?

No public merits judgment was entered. The case was resolved by settlement, so the docket does not establish a judicial victory for either side.

Were Doryx patents invalidated?

No. The Mayne-Padagis proceeding did not produce a public invalidity judgment.

Is Doryx protected by biologic exclusivity?

No. Doryx is a small-molecule doxycycline product regulated through the ANDA pathway.

Can another generic company rely on the Padagis settlement?

Not necessarily. The agreement’s terms were confidential and may have applied only to Padagis, its ANDA, specified products, or a negotiated launch date.

References

1. U.S. District Court for the District of Delaware. (2021). Mayne Pharma LLC v. Padagis Israel Pharmaceuticals Ltd., No. 1:21-cv-00612, docket materials.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

3. Hatch, Waxman, and related amendments to the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

4. U.S. Patent Act, 35 U.S.C. § 271(e)(2).